Advisor Group Inc. trimmed its holdings in Sanofi (NYSE:SNY) by 5.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,990 shares of the company’s stock after selling 3,507 shares during the quarter. Advisor Group Inc.’s holdings in Sanofi were worth $3,036,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in SNY. Parallel Advisors LLC boosted its holdings in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares in the last quarter. Eagle Ridge Investment Management acquired a new position in Sanofi in the second quarter valued at approximately $160,000. Bronfman E.L. Rothschild L.P. boosted its holdings in Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares in the last quarter. Finally, Toronto Dominion Bank lifted its stake in Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after buying an additional 180 shares during the last quarter. 9.36% of the stock is owned by hedge funds and other institutional investors.
SNY has been the subject of a number of research reports. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. BidaskClub cut Sanofi from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Finally, Argus reiterated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $53.50.
Sanofi (NYSE:SNY) traded up $0.01 during trading on Wednesday, hitting $44.65. The stock had a trading volume of 610,800 shares, compared to its average volume of 1,529,478. Sanofi has a twelve month low of $38.45 and a twelve month high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market capitalization of $112,560.12, a PE ratio of 14.08, a PEG ratio of 2.46 and a beta of 0.88.
TRADEMARK VIOLATION NOTICE: This article was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/11/15/sanofi-sny-shares-sold-by-advisor-group-inc.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.